New inhaled TB drug shows promise in early trial
NCT ID NCT07073638
First seen Jan 12, 2026 · Last updated May 17, 2026 · Updated 18 times
Summary
This study tests a new inhaled medicine called RESP30TB in 24 adults recently diagnosed with a common type of lung tuberculosis (TB). The main goal is to see if the drug is safe and can quickly reduce TB bacteria in the lungs. Participants will receive the drug through a nebulizer (a machine that turns liquid medicine into a mist to breathe in).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY TUBERCULOSES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
TASK Clinical Research Centre
RECRUITINGCape Town, Bellville, 7531, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.